Drugs / SHR-4602
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06560138 | Mar → Dec 2025 | — | Atridia Pty Ltd. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05819684 | Apr 2023 → May 2025 | neoplasm | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06704828 | Dec 2024 → Apr 2027 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06516926 | Aug 2024 → Nov 2025 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-4602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05582499 ↗ |
| Modality | Monoclonal antibody | “an anti-HER2 ADC” NCT05582499 ↗ |
| Route | Intravenous | “be administered via intravenous (IV) infusion” NCT05819684 ↗ |